Headquartered in Carlsbad, CA Fiscal year ends December NASDAQ: IONS ionis.com
Ionis Pharmaceuticals is a biotechnology company that has pioneered RNA-targeted medicines for over three decades. The company develops and commercializes antisense therapies across neurology, cardiometabolic disease, and other areas of high unmet medical need. Its wholly owned commercial portfolio includes TRYNGOLZA (olezarsen) for severe hypertriglyceridemia, DAWNZERA (donidalorsen) for hereditary angioedema, and a deep pipeline spanning Alexander disease (zilganersen), Angelman syndrome (obudanersen), and next-generation triglyceride-lowering candidates (ION775). Ionis also generates substantial royalty revenue from partnered medicines including SPINRAZA (nusinersen) for spinal muscular atrophy (marketed by Biogen) and WAINUA (eplontersen) for hereditary transthyretin-mediated amyloidosis polyneuropathy (marketed by AstraZeneca). The company earns R&D revenue from collaborative agreements with major pharmaceutical partners including GSK (bepirovirsen for chronic hepatitis B), Novartis (pelacarsen for Lp(a)-driven cardiovascular disease), Biogen, AstraZeneca, and Ono Pharmaceutical. Ionis continues to advance new approaches in gene editing alongside its core RNA therapeutics platform. Updated
A Phase 3 trial failure has erased a year of gains for Ionis Pharmaceuticals in just days, and the ripple effects are rattling rivals across the RNA and rare-disease biotech space with…
BridgeBio Pharma (NASDAQ:BBIO | BBIO Price Prediction) received a Neutral initiation from Citi Neutral on Tuesday, reflecting a measured stance on the company’s transthyretin amyloid cardiomyopathy (ATTR-CM) franchise. The call contrasts with…
Ionis Pharmaceuticals (NASDAQ:IONS | IONS Price Prediction) has delivered a remarkable 137.52% gain over the past year, though the stock has pulled back 6.12% year-to-date and sits 7.20% below its one-month high,…
Joel South Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Viking Therapeutics.
Tuesday's top analyst upgrades and downgrades included BioNTech, ConocoPhillips, Harley-Davidson, Livent, Luminar Technologies, Meta Platforms, Moderna, Snap, Twitter, United Airlines, US Foods, Workday and Wells Fargo.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Friday, including Etsy, Fate Therapeutics, Intellia, Ionis, Monster Beverage and more.
Akcea Therapeutics stock jumped on Monday after it was announced that Ionis Pharmaceuticals would be acquiring all of its outstanding shares.
Chris Lange Akcea Therapeutics and Ionis Pharmaceuticals each made handy gains on Wednesday after the firms reported midstage results for their cardiovascular disease study.
Chris Lange Ionis Pharmaceuticals is a biotechnology company that has pioneered RNA-targeted medicines for over three decades. The company develops and commercializes antisense therapies across neurology, cardiometabolic disease, and other areas of high unmet medical need.
The Wall Street consensus 12-month price target for IONS is $83.64. IONS price prediction →
